

**Drug Utilization Review Board Meeting Minutes**  
**February 25, 2015**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

**Members Present:**

Lester Labus, MD, Chair  
Kc Lovin, PA-C, Vice Chair  
C.K. Babcock, PharmD  
Christopher Booth, PharmD  
Scott Brown, RPh  
Myra Chiang, MD  
Karen Fitzpatrick, MD  
Kate Forman, PharmD  
Michel Lonsinger, PharmD  
Ernest Miller, DO (via phone)  
Mary Nemeth-Pyles, MSN, RN, CS  
Chris Terpening, PharmD, PhD

**Members Absent:**

John Vanin, MD  
Pat Regan, PharmD

**DHHR/BMS Staff Present:**

Vicki Cunningham, RPh, Director of Pharmacy Services  
Brian Thompson, MS, PharmD, DUR Coordinator  
Bill Hopkins, Pharmacy Operations Manager  
Doug Sorvig, Administrative Assistant  
James Becker, MD, Medical Director (via phone)  
Paula Hamady, FNP

**Contract Staff:**

Steve Small, M.S., RPh, Rational Drug Therapy Program (RDTP)  
Eric Sears, RPh, Molina Medicaid Solutions  
Nina Bandali, PharmD, Magellan Healthcare  
Giovanni Perri, MD, Magellan Healthcare  
Steve Espy, RPh, CPh, Health Information Design (HID)

- I. **INTRODUCTIONS** - Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting (16:08). The DUR Board and attendees introduced themselves. A motion was made, seconded and approved to accept the minutes from the previous DUR Board Meeting.
  
- II. **OLD BUSINESS**
  - A. None

### III. **NEW BUSINESS**

#### A. **Speakers: 4 speakers**

- 1 Margaret Wooddell - Mylan – EpiPen
- 2 Eric Bizjak - Shire – Firazyr/Cinryze
- 3 Sharmi Patel – Genentech - Esbriet
- 4 Scott Cullins – V&G & Associates (on behalf of Silver Gate Pharmaceuticals) – Epaned

#### B. **Updates from January 28, 2015 P&T Committee Meeting:**

- 1 Dr. Labus reviewed the changes to the PDL and associated prior authorization criteria from the January 28, 2015 P&T Committee meeting. A motion was made, seconded and passed accepting the current criteria with the following changes:
  - a. Epinephrine, Self-Injected - A non-preferred agent will be authorized upon documentation showing the patient's inability to follow the instructions, or the patient's failure to understand the training for both preferred agents.
  - b. Hepatitis C Agents - See Attachment A for Viekira Pak and Harvoni Changes
  - c. Neuropathic Pain – Horizant - Add a gabapentin trial for diagnosis of RLS
- 2 Attachment A (HEP-C Agents)
- 3 Attachment B (Neuropathic Pain - Horizant)
- 4 Attachment C (PDL Changes)

#### C. **First Dose Limits on Oncology Agents**

- 1 The Bureau was not ready to present recommendations at this meeting and the Board agreed to postpone this discussion until May's meeting.

#### D. **Prior Authorization Criteria**

- 1 Linzess – Motion to approve was made, seconded and passed.
- 2 Epaned - Motion to approve was made, seconded and passed.
- 3 Jublia - Motion to approve was made, seconded and passed.
- 4 Cinryze & Firazyr - Motion to postpone the review of the criteria for this drug until the next DUR Board meeting was made, seconded and passed.
- 5 Esbriet - Motion to approve was made, seconded and passed.  
Attachment D

### IV. **REPORTS**

A. **Molina Quarterly Report –Second Quarter 2014** - Eric Sears gave an overview of the Molina 2014 Fourth Quarter Report. The presentation included a review of the DUR Quarterly Overall Summary Report.  
See Attachment E

B. **Rational Drug Therapy Program** - Steve Small gave a slide presentation overview of the program activities for the fourth quarter.  
See Attachment F

C. **HID** – Steve Espy gave a slide presentation overview of West Virginia's Retro DUR fourth quarter activity.  
See Attachment G

VI. **OTHER BUSINESS - OPEN TO THE FLOOR**

A. None

VII. **NEXT MEETING AND ADJOURNMENT**

A. A motion was made, seconded and approved to adjourn the meeting.

B. The meeting concluded at 5:53 p.m.

C. The next meeting will be Wednesday, May 27, 2015 from 4:00 PM-6:00 PM located at the WVDHHR.

Submitted by:

Brian M. Thompson, PharmD